Form 4: Bluebird Bio CEO Andrew Obenshain Acquires and Disposes of Shares to Cover Tax Obligations

Sentiment:

SEC Form 4


Andrew Obenshain, CEO of Bluebird Bio, reports acquisition of 130,000 shares of common stock and disposition of 34,780 shares to cover tax obligations related to vesting restricted stock units.

Summary

  • On September 30, 2024, Andrew Obenshain, the President and CEO of bluebird bio, Inc., acquired 130,000 shares of common stock.
  • The acquisition was related to restricted stock units vesting over a four-year period.
  • On the same day, Obenshain disposed of 34,780 shares of common stock at an average price of $0.5253 to cover tax withholding obligations.
  • Following these transactions, Obenshain beneficially owns 375,218 shares of bluebird bio, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates

DateDescription
09/23/2024Date of Power of Attorney execution.
09/30/2024Date of stock acquisition and disposition.
03/01/2025First vesting date of restricted stock units.
03/01/2026Second vesting date of restricted stock units.
03/01/2027Third vesting date of restricted stock units.
03/01/2028Final vesting date of restricted stock units.
10/02/2024Date of signature by Attorney-in-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.